A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Recombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent pre-existing anti vector immunity. This study describes the derivation of a...

Full description

Saved in:
Bibliographic Details
Main Authors: Matthew D J Dicks, Alexandra J Spencer, Nick J Edwards, Göran Wadell, Kalifa Bojang, Sarah C Gilbert, Adrian V S Hill, Matthew G Cottingham
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040385&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849727567444049920
author Matthew D J Dicks
Alexandra J Spencer
Nick J Edwards
Göran Wadell
Kalifa Bojang
Sarah C Gilbert
Adrian V S Hill
Matthew G Cottingham
author_facet Matthew D J Dicks
Alexandra J Spencer
Nick J Edwards
Göran Wadell
Kalifa Bojang
Sarah C Gilbert
Adrian V S Hill
Matthew G Cottingham
author_sort Matthew D J Dicks
collection DOAJ
description Recombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent pre-existing anti vector immunity. This study describes the derivation of a new vaccine vector based on a chimpanzee adenovirus, Y25, together with a comparative assessment of its potential to elicit transgene product specific immune responses in mice. The vector was constructed in a bacterial artificial chromosome to facilitate genetic manipulation of genomic clones. In order to conduct a fair head-to-head immunological comparison of multiple adenoviral vectors, we optimised a method for accurate determination of infectious titre, since this parameter exhibits profound natural variability and can confound immunogenicity studies when doses are based on viral particle estimation. Cellular immunogenicity of recombinant E1 E3-deleted vector ChAdY25 was comparable to that of other species E derived chimpanzee adenovirus vectors including ChAd63, the first simian adenovirus vector to enter clinical trials in humans. Furthermore, the prevalence of virus neutralizing antibodies (titre >1:200) against ChAdY25 in serum samples collected from two human populations in the UK and Gambia was particularly low compared to published data for other chimpanzee adenoviruses. These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use.
format Article
id doaj-art-e7199a2be3424c0ea10dfbee38ad80e6
institution DOAJ
issn 1932-6203
language English
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-e7199a2be3424c0ea10dfbee38ad80e62025-08-20T03:09:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4038510.1371/journal.pone.0040385A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.Matthew D J DicksAlexandra J SpencerNick J EdwardsGöran WadellKalifa BojangSarah C GilbertAdrian V S HillMatthew G CottinghamRecombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent pre-existing anti vector immunity. This study describes the derivation of a new vaccine vector based on a chimpanzee adenovirus, Y25, together with a comparative assessment of its potential to elicit transgene product specific immune responses in mice. The vector was constructed in a bacterial artificial chromosome to facilitate genetic manipulation of genomic clones. In order to conduct a fair head-to-head immunological comparison of multiple adenoviral vectors, we optimised a method for accurate determination of infectious titre, since this parameter exhibits profound natural variability and can confound immunogenicity studies when doses are based on viral particle estimation. Cellular immunogenicity of recombinant E1 E3-deleted vector ChAdY25 was comparable to that of other species E derived chimpanzee adenovirus vectors including ChAd63, the first simian adenovirus vector to enter clinical trials in humans. Furthermore, the prevalence of virus neutralizing antibodies (titre >1:200) against ChAdY25 in serum samples collected from two human populations in the UK and Gambia was particularly low compared to published data for other chimpanzee adenoviruses. These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040385&type=printable
spellingShingle Matthew D J Dicks
Alexandra J Spencer
Nick J Edwards
Göran Wadell
Kalifa Bojang
Sarah C Gilbert
Adrian V S Hill
Matthew G Cottingham
A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
PLoS ONE
title A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
title_full A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
title_fullStr A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
title_full_unstemmed A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
title_short A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.
title_sort novel chimpanzee adenovirus vector with low human seroprevalence improved systems for vector derivation and comparative immunogenicity
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0040385&type=printable
work_keys_str_mv AT matthewdjdicks anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT alexandrajspencer anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT nickjedwards anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT goranwadell anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT kalifabojang anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT sarahcgilbert anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT adrianvshill anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT matthewgcottingham anovelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT matthewdjdicks novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT alexandrajspencer novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT nickjedwards novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT goranwadell novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT kalifabojang novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT sarahcgilbert novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT adrianvshill novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity
AT matthewgcottingham novelchimpanzeeadenovirusvectorwithlowhumanseroprevalenceimprovedsystemsforvectorderivationandcomparativeimmunogenicity